|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Paired box family protein 8 (PAX8) has been described as a transcription factor highly specific to neoplasms derived from Mullerian organs, thyroid, and kidney.
|
30358609 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MYC silencing increased expression levels of PAX8‑AS1:28 and PAX8 and inhibited tumor cell growth, while MYC overexpression decreased expression levels of PAX8‑AS1:28 and PAX8 and promoted tumor cell growth.
|
30720110 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We investigated the expression of PAX8 in SFTs and other spindle cell RP tumors.
|
28749793 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EMA, GATA3, and PAX8 were positive in 2/10 (20%; focal), 3/15 (20%; focal), and 1/15 (7%; focal) of tumors, respectively.
|
31591497 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAX8 exerts a tumor-suppressive effect against gastric cancer cells, largely through induction of miR-612 and repression of FOXM1.
|
30021604 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Pax-8 protein is commonly used for differentiating peritoneal MM from serous carcinoma, but the diagnostic value of Pax-8 for distinguishing WDPM from borderline or low-grade serous tumors is unknown.
|
29241740 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical studies showed that the tumor cells were positive for markers of ovarian origin such as PAX-8 and CA-125 and negative for breast markers such as GATA-3, thus supporting the diagnosis.
|
29194708 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In our case, especially the immunohistochemical profile of the tumor with diffuse positivity for cytokeratin 7 and PAX8, and no expression of cytokeratin 20 and CDX2, directed us toward a primary ovarian origin.
|
28463910 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical studies showed that all ATCs lost TTF-1 and thyroglobulin expression, whereas PAX-8 expression was identified in 36% (4/11) of tumors.
|
30075157 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HMB45 and PAX8 staining were detected in six of seven tumors.
|
29052596 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The two main competing hypotheses for the etiology of these neoplasms are development either by metaplasia of the mesothelium of the tunica vaginalis testis, or from remnants of Mullerian duct, which is supported by the notable positivity for PAX8 in our case.
|
27597522 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, their work establishes that <i>Bap1</i> and <i>Pbrm1</i> are determinants of tumor grade and mTORC1 activation and provocatively suggests that the cell of origin of ccRCC may lie in PAX8-expressing Bowman capsule cells.<i>Cancer Discov; 7(8); 802-4.
|
28765116 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical evaluation on the biopsy reveals that the tumor is positive for PAX-8, CD10, and TFE3.
|
28877071 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cell lines expressed AE1/AE3, Pax8, WT-1, OC125, estrogen receptor (ER), and p53, comparable to the primary tumor.
|
28604461 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The majority of SCC were PAX8 negative (92%; 95/103), whereas among the endocervical adenocarcinomas PAX8 was positive in 70% (14/20) of the usual type and in 83% (5/6) of the endometrioid-type tumors.
|
27362905 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Co-expression of cytokeratin and vimentin by the tumor raised the possibility of metastatic renal cell carcinoma and positivity of the tumor for PAX8 supported this hypothesis.
|
28675457 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no significant difference in the tumour expression of either WT1 or PAX8 between the three Malaysian ethnicities.
|
28367736 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of PAX2/PAX8 in S-SCT may reflect an overactive epithelial-to-mesenchymal transition as has been shown in experimental models of acute and chronic seminiferous tubular injury and might be related to the process generating the stroma in these tumors.
|
28873352 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pax8 and peroxisome proliferator-activated receptor gamma 1 gene (Pax8-PPARγ1) are important factors in tumors.
|
27797226 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PAX8 gene gives rise to four isoforms, through alternative mRNA splicing, but the splicing pattern in tumors is not yet established.
|
27175788 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAX8 is a transcription factor expressed in fallopian tube epithelial cells and in 80-96% of HGSC tumors.
|
27129161 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical studies demonstrated the tumor cells to be PAX-8 (+), pancytokeratin (+, focally), TTF-1 (-) and SOX-10 (-).
|
26347145 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A review of the literature shows lack of site-specific studies with regards to the expression of PAX8 in the central nervous system and its neoplasms.
|
26371431 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically (IHC), the tumor cells are positive for TFE3 and the renal tubular markers (PAX2 and PAX8), and completely negative for SMARCB1, an oncosuppressor protein.
|
27733182 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunostains for epithelial membrane antigen (EMA), CK7, OSCAR, CD117, parvalbumin, MIA, and Pax 8 were positive in all tumors while negative for vimentin, TFE3, CANH 9, HMB45, cathepsin K, and AMACR.
|
27631338 |
2016 |